First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
This strategic collaboration will enable continued innovation in cancer care
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)